Церамиды как фактор риска неалкогольной жировой болезни печени

Л. Л. Павловський, В. В. Чернявський


Сегодня одним из факторов патогенеза неалкогольной жировой болезни печени, которые заслуживают особого внимания, является накопление специфических липидных подвидов в печени – церамидов. В статье освещены следующие вопросы: что же собой представляют церамиды, как они образуются, каким образом они влияют на апоптоз и развитие инсулинорезистентности.

Ключевые слова

неалкогольная жировая болезнь печени; церамиды; апоптоз; инсулинорезистентность

Полный текст:



Vernon, G., Baranova, A., and Younossi, Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274–85

Angulo P. GI Epidemiology: nonalcoholic fatty liver disease. P. Angulo // Alimentary Pharmacology & Therapeutics. – 2007. – V. 25. – P.883–889.

Oh M.K. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. M.K.Oh, J.Winn, F. Poordad // Ailment Pharmacol Ther. – 2008. – Vol. 28. – P. 503–522.

Exendin-4 improves steatohepatitis by increasing Sirt1 expression in highfat diet-induced obese C57BL/6J mice. J Lee, SW Hong, SW Chae et al. // PloS One. – 2012. –Vol.7, N2. – P.63–72.

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. K Promrat, DE Kleiner, HM Niemeier, E Jackvony et al. // Hepatology. – 2010. – V51. – P121–129

Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in type 2 diabetic patients. Diabetes Care 2007; 30:1212–1218.

Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007; 6(3):161–163. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, ho K, Sung IK. PDF

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285

EASL–EASD–EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease 2016

Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13:511–31.

Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014; 15:8591–638.

Bugianesi E, Moscatiello S, Ciaravella MF, et al. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16:1941–51.

Cusi K. Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13:545–63.

Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016, Apr;15(4):249–74.

Castro, B. M., Prieto, M. & Silva, L.C. Ceramide: a simple sphingolipid with unique biophysical properties. Prog. Lipid Res. 54, 53–67 (2014).

Gault, C.R. et al. (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol. 688, 1–23 Full text

Frangioudakis, G. et al. (2010) Saturated-and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. Endocrinology 151, 4187–4196

Chocian, G. et al. (2010) High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei. Mol. Cell. Biochem. 340, 125–131

Nikolova-Karakashian, M.N. and Rozenova, K.A. (2010) Ceramide in stress response. Adv. Exp. Med. Biol. 688, 86–108

Holland, W.L. and Summers, S.A. (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381–402

Clarke, C.J. et al. (2006) The extended family of neutral sphingomyelinases. Biochemistry 45, 11247–11256

Mari, M. and Fernandez-Checa, J.C. (2007) Sphingolipid signalling and liver diseases. Liver Int. 27, 440–450

Summers, S.A. (2006) Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42–72

Semple, R.K. et al. (2009) Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Invest. 119, 315–322

JeBailey, L. et al. (2007) Ceramide and oxidant-induced insulin resistance involve loss of insulin-dependent Racactivation and actin remodeling in muscle cells. Diabetes 56, 394–403

Ribaux, P.G. and Iynedjian, P.B. (2003) Analysis of the role of protein kinase B (cAKT) in insulin-dependent induction of glucokinase and sterol regulatory element-binding protein 1 (SREBP1) mRNAs in hepatocytes. Biochem. J. 376, 697–705

Colombini, M. (2010) Ceramide channels and their role in mitochondriamediated apoptosis. Biochim. Biophys. Acta 1797, 1239–1244

Mari, M. et al. (2008) Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 134, 1507–1520

Edelmann, B. et al. (2011) Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J. 30, 379–394

Mangesh Pagadala, Takhar Kasumov,Arthur J. McCullough,Nizar N. Zein,and John P. Kirwan Role of Ceramides in Nonalcoholic Fatty Liver Disease Trends Endocrinol Metab. 2012 Aug; 23(8): 365–371.

Copyright (c) 2020 Л. Л. Павловський, В. В. Чернявський

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter